Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

215
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
215
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

14.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
14.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

3DOpt: Benchmark for Automated Design of 3D Molecular Structures across the Periodic Table.

Journal of chemical information and modeling·2026
Same author

REINFORCE-ING Chemical Language Models for Drug Discovery.

Journal of chemical information and modeling·2025
Same author

Synthesis and Inhibitory Assessment of ACE2 Inhibitors for SARS-CoV-2: An <i>In Silico</i> and <i>In Vitro</i> Study.

The Journal of organic chemistry·2025
Same author

Navigating protein landscapes with a machine-learned transferable coarse-grained model.

Nature chemistry·2025
Same author

QuantumBind-RBFE: Accurate Relative Binding Free Energy Calculations Using Neural Network Potentials.

Journal of chemical information and modeling·2025
Same author

Broadening the Scope of Neural Network Potentials through Direct Inclusion of Additional Molecular Attributes.

Journal of chemical theory and computation·2025

相关实验视频

Updated: Jan 9, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K

在药物设计中进行化学探索的测试时间培训缩放规律.

Morgan Thomas1,2, Albert Bou1, Gianni De Fabritiis1,3,4

  • 1Computational Science Laboratory, Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), C Dr. Aiguader 88, 08003 Barcelona, Spain.

Journal of chemical information and modeling
|December 9, 2025
PubMed
概括

化学语言模型 (CLMs) 的测试时间培训 (TTT) 的扩展与强化学习 (RL) 显著改善了分子探索. 增加RL剂,而不是培训时间,提高了用于药物设计的多种分子的发现.

更多相关视频

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.4K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.2K

相关实验视频

Last Updated: Jan 9, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.4K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.2K

科学领域:

  • 人工智能的人工智能是人工智能.
  • 计算化学是一种计算化学.
  • 药物发现 药物发现

背景情况:

  • 使用强化学习 (RL) 的化学语言模型 (CLM) 用于 de novo 分子设计.
  • 模式崩限制了CLM在化学空间的探索能力.
  • 大型语言模型中的测试时间培训 (TTT) 激发了新的方法.

研究的目的:

  • 通过扩大TTT来增强CLM中的化学太空探索.
  • 推出MolExp,用于评估具有相似生物活性的多种分子发现的基准.
  • 调查扩展TTT战略对勘探效率的影响.

主要方法:

  • 建议通过增加独立RL代理人数量来扩大CLM的TTT.
  • 引入了MolExp基准,用于评估结构多样化的分子生成.
  • 评估了TTT培训时间和合作的RL策略的影响.

主要成果:

  • 通过更多的RL代理来扩展TTT遵循了日志线性规律,提高了MolExp的勘探效率.
  • 增加的TTT培训时间显示,勘探的回报正在减少.
  • 评估了合作的RL战略,以加强勘探.

结论:

  • 使用多种RL剂缩放TTT为高效的分子探索提供了可行的策略.
  • 这些发现表明,产生性分子设计的可扩展框架.
  • 优化人工智能驱动的药物发现可以从这些对探索效率的见解中受益.